Clinical healing of antimony - resistant cutaneous or mucocutaneous Leishmaniasis following the combined administration of IFN-g and pentavalent antimonials (Sb v)

Abstract

In a phase II open trial, combined therapy with SbV (10mg/kg body weight), and recombinant human IFN-g (100 µg/m2 body surface area), was administered to 13 patients with diagnosis of cutaneous or mucocutaneous leishmaniasis, clearly unresponsive to antimony. Daily intramuscular injections of both compounds were given during 30 days, but treatment could be continued up to 90 days in case of partial healing of lesions. Four of them presented with large skin ulcers, and nine had mucosal involvement as main manifestation. The latter affecting the nose, 3 cases, nose and septum ,2 cases, nose and oral cavity, 1 case, and nose pharynx and larynx, 3 cases. Except for a case with severe involvement of the upper respiratory tract, remaining 11 patients, completing treatment ...